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Human helminth therapy to treat inflammatory
disorders- where do we stand?
Helena Helmby
Abstract
Parasitic helminths have evolved together with the mammalian immune system over many millennia and as such
they have become remarkably efficient modulators in order to promote their own survival. Their ability to alter and/
or suppress immune responses could be beneficial to the host by helping control excessive inflammatory responses
and animal models and pre-clinical trials have all suggested a beneficial effect of helminth infections on inflammatory
bowel conditions, MS, asthma and atopy. Thus, helminth therapy has been suggested as a possible treatment method
for autoimmune and other inflammatory disorders in humans.
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Introduction
The hygiene hypothesis
One of the first reports suggesting a link between envir-
onmental living conditions and allergic disease originates
already from the 1970s [1] where members of a predom-
inant urban white community was reported to have
higher levels of allergic disease, compared to a rural
indigenous community where levels of viral, bacterial
and helminth infections were much higher. A similar
observation was made by Strachan a decade later, report-
ing that children with elder siblings were less likely to
develop hay fever leading to the original Hygiene hy-
pothesis proposal, hypothesising that reduced exposure
to infections in early childhood owing to a combination
of diminishing family size, improved living standards
and higher levels of personal hygiene might result in
increased risk of developing allergic disease later in life
[2]. The hypothesis has since been extended to include
other types of immune-mediated and inflammatory disor-
ders such as autoimmune diseases (e.g. multiple sclerosis
(MS)) and inflammatory bowel disease (IBD) [3,4], all con-
ditions with a sharp increase in prevalence throughout
westernised high-income countries in the last few decades
[5]. This increase in immune-mediated disorders correlate
with urbanisation and economic development but which
specific aspects of the westernised lifestyle that are
responsible have not yet been clearly defined. Changes in
air pollution levels, increased indoor exposure to allergens
and general improvement of living standards have all been
implicated. In addition, childhood exposure to changes in
intestinal microbiota [6] and a variety of pathogenic mi-
crobes, including helminths, have also been suggested to
play a part. Helminth infections, in particular intestinal
worms, were up to a few decades ago common in all parts
of the world but have now been more or less eradicated in
high-income countries, despite still being a major public
health problem in the rest of the world. The ability of
worms to modulate the host response to a state of what
can be described as “anti-inflammatory tolerance” to-
gether with the sharp increase in inflammatory disorders,
paralleled with the decrease in helminth infections in high
income countries, has generated a strong interest in the
possibility that worms, or their products, could be used as
new anti-inflammatory treatments.
Helminth-induced immune responses
Work in mouse models have clearly established that
immunity to intestinal helminths is dependent on a Type
2 cytokine response, involving the secretion of IL-4,
IL-5, IL-9 and IL-13 and the subsequent activation of
intestinal mast cells, eosinophils, goblet cells, enterocyte
proliferation and intestinal contractility (reviewed in [7]).
In addition, Type 2 responses promote the “walling off ”
of eggs or larvae in tissues via granuloma formation as
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well as promoting tissue repair mechanisms, an important
component of infections with large metazoan parasites as
evidenced by the fact that a failure to mount a Type 2
response is generally associated with increased pathology
and tissue destruction [8]. In addition to a Type 2 response,
various immunoregulatory mechanisms are induced,
including increases in regulatory T cell (T reg) numbers
and IL-10 and/or TGF-β levels, resulting in a highly
anti-inflammatory environment. Studies have highlighted
the importance of IL-10 in controlling pathology associ-
ated with helminth infections as IL-10 deficient mice
suffer higher mortality and/or morbidity [9,10], whilst
depletion of T regulatory cells in vivo result in increased
immune responses and parasite clearance [11,12]. Overall
there is substantial evidence that the increased regulatory
activity during helminth infection need to strike a fine bal-
ance between protection against pathology and clearance
of the infection. Since helminths are so good at generating
immunoregulatory mechanisms, the question naturally
arises as to whether helminth replacement therapy may
have a therapeutic role to play in the treatment of auto-
immune and allergic disorders.
Review
Helminth therapy in humans
To date two species of helminths have been tested for
human helminth therapy as a clinical treatment, Trichuris
suis, the pig whipworm, and the human hookworm Necator
americanus. After ingestion of T.suis ova (TSO), the eggs
hatch and the worms colonise the caecum and colon of the
human gut for only a short period of time (weeks) meaning
that treatments need to be repeated at intervals, however,
this species-specificity and lack of chronic infection is bene-
ficial in the sense that it also removes any wider public
health issues. Larvae of the human hookworm Necator,
however, are administered percutaneously and migrate
through the vasculature and lungs to the small intestine
where they survive by feeding on blood from the mucosa,
giving rise to long lasting infections (years) and may at
higher doses cause clinical symptoms such as gastrointes-
tinal symptoms and anemia. In its natural state this infec-
tion is a major public health problem across the globe and
large-scale deworming programs are in place to combat the
morbidity associated with natural infection [13].
Helminth therapy used to alleviate intestinal
inflammation
Several studies in animal models have demonstrate that
intestinal helminth infections are able to inhibit the
development of intestinal inflammation (reviewed in
[14,15]) and the first clinical studies of helminth therapy
in humans started some 10–15 years ago with the use of
the pig whipworm Trichuris suis. In initial safety studies
patients with Ulcerative colitis (UC) or Crohn’s disease
were given viable, embryonated T.suis eggs (TSO) and not
only was the treatment well tolerated but a significant dis-
ease remission was observed and although the beneficial
effect was temporary, repeated doses of TSO sustained
this clinical improvement suggesting a promising new
therapy for IBD [16,17]. A placebo–controlled, double
blind, randomised trial in Ulcerative colitis patents
followed, showing significantly improved disease activity
index in TSO treated patients compared to placebo, al-
though the remission rate was no different between the
two groups [18]. Further development and safety testing
of TSO under GMP was performed and a small random-
ized double-blind placebo controlled study reported that
Crohn’s patients receiving a single dose of up to 7500
TSO did not show any short (2 weeks) or long term
(6 months) adverse effects [19] opening up the field to-
wards larger clinical trials. To date at least six clinical trials
using TSO in Crohn’s or UC patients have been registered
as recruiting, ongoing or completed. However, in October
2013 Coronado biosciences announced in a press release
that the results from the first larger study (TRUST-1, trial
identifier NCT01576471), a Phase 2 clinical trial evaluat-
ing TSO in 250 US patients with moderate-to-severe
Crohn’s disease, did not meet its primary endpoint of
improving responses, either in terms of improving dis-
ease activity index or remission rates, although a non-
significant improvement was noted in patients with a
more severe disease score [20]. Shortly after, a second
Corona press release announced the discontinuation of
the Phase 2 study of 240 European Crohn’s patients
(FALK, trial identifier NCT01279577) after an independ-
ent monitoring committee recommended its discontinu-
ation due to “lack of efficacy” [21]. No further data has
been released from either study. Although the clinical trial
results for TSO therapy in Crohn’s patients are disap-
pointing, results from several Ulcerative colitis trials are
still eagerly awaited.
A second approach to helminth therapy has been the
slightly more controversial use of the human hookworm
Necator, a pathogen responsible for much of the morbid-
ity associated with intestinal helminth infections around
the globe. In a small trial where 9 Crohn’s patients were
infected with 25–50 larvae and followed over 20 weeks,
7 patients experienced improved disease score while 2
experienced a worsening effect [22]. A second study ex-
amined hookworm versus placebo therapy in a cohort
of 20 coeliac disease (gluten allergy) patents followed
by wheat challenge after 20 weeks. The dose of 5–10
larvae was generally well tolerated and immunological
analysis demonstrated reduced inflammatory cytokine
(IFN-γ and IL-17) responses in duodenal biopsies from
hookworm compared to placebo-treated patients [23],
however there was no difference in the symptomatic re-
sponse to wheat challenge with all subjects experiencing
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the same levels of clinical symptoms regardless of treat-
ment [24]. Further clinical trails of using hookworm infec-
tions in coeliac patients are still expected.
Helminth therapy and allergy
Another field of much interest in recent years is whether
helminth therapy may be useful in reducing allergic
symptoms. Several studies from helminth endemic areas
have suggested that certain helminth infections may pro-
tect against allergy and asthma but a systematic review
of 33 published studies concluded that there was no
overall protective effect of helminth infections in general
on asthma [25]. However, concurrent hookworm infec-
tion was associated with a protective effect, which was
infection-intensity dependent. In contrast, concurrent
Ascaris lumbricoides infection, another common intes-
tinal nematode infection, was associated with a signifi-
cantly increased risk of asthma. This is particularly
interesting given the fact that both hookworms and
Ascaris pass through the lungs during their migration to
the intestine but only Ascaris is being known as causing
tropical pulmonary eosinophilia syndrome, due to its high
allergenicity [25], thus demonstrating that only certain
specific helminth species are likely to be beneficial from a
helminth therapy perspective.
Studies on the relationship between helminth infection
and atopy have also generated mixed results with both
positive and negative associations depending on the
species of worms involved [26] and deworming studies
in helminth endemic communities have either shown no
evidence for increased skin prick test (SPT) reactivity
[27], or increased SPT reactivity [28,29]. However, aller-
gen SPT reactivity may also be influenced by worm
infections due to the fact that many helminth antigens
crossreact with common allergens and it may be that the
release of helminth antigens from dying worms after anti-
helminthic treatment may increase reactivity temporarily.
In this context it is important to recognize that several
highly immunogenic helminth proteins share structural
relationships with a number of common allergens, for
example, IgE cross-reactivity has been demonstrated
between helminth (e.g. filarial and Ascaris) tropomyosins
and the tropomyosins of house dust mite (Der p 10) and
cockroaches (Bla g 7) suggesting that helminth infections
may well be able to enhance allergic reactivity. The num-
ber of potentially cross-reactive proteins shared among
helminths and allergens has been suggested to be very
extensive, with 40% of 499 molecularly defined allergen
families having homologs in helminth parasite genomes
[30-32].
In the light of a large body of literature suggesting some
protective benefits of helminth infections on allergy and
asthma a few human helminth therapy trials in asthma/
allergy have been published. The first one, a randomized
trial using 8 doses of TSO, or placebo, at an interval of
21 days in 100 patients with grasspollen-induced allergic
rhinitis showed no significant effect on rhinitis symptoms,
grass-specific IgE levels, or SPT reactivity, despite indu-
cing T.suis-specific antibody responses and gastrointes-
tinal symptoms [33]. Similarly, a small randomized safety
study in individuals with allergic rhinoconjunctivitis
treated with hookworm larvae or placebo, and followed
for 12 weeks, reported no significant effects on lung
function, SPT or rhinconjunctivitis symptoms, despite
clear evidence of hookworm-induced responses such as
increased eosinophilia and gastrointestinal symptoms
[34]. Another small randomized control trial in patients
with asthma again showed no significant benefit of hook-
worm infection on clinical symptoms, bronchial responsive-
ness or SPT reactivity [35]. It should be noted, however,
that both the hookworm studies were small studies with 15
and 16 patients in each group, respectively, and using low
doses of larvae (10), while the timing of infection in relation
to pollen season may also need to be adjusted to reach opti-
mal affects. As such, further trials are required in order to
draw any firm conclusions on the potential benefits in using
helminth therapy against allergies and asthma.
There are a number of potential reasons why the results
from human trials have not generated more positive data.
A large number of animal studies have demonstrated a
potent ability of a variety of helminth infections to reduce
allergic reactivity in mice and rats (reviewed in [14]), how-
ever the vast majority of studies have shown this as an
ability to prevent the development of allergic reactivity
after exposure to helminths, and only a handful have
reported the ability for the infections to impact an already
established allergic reactivity. Furthermore, a few animal
studies have also reported the inability of helminth infec-
tions to alter such an established allergic response. As
such, most of the experimental data available suggest that
once the allergic reaction is established helminth infec-
tions can do little to alter this, raising the inevitable ques-
tion whether there is any true benefit to gain from
helminth therapy in already allergic individuals. Regard-
less, in terms of the disappointing clinical trials in humans
there are still question remaining surrounding whether
optimal timing of treatment, the dose and whether sys-
temic versus non-systemic infections may play an import-
ant part. TSO is entirely restricted to the intestine and
may not induce sufficient systemic response to alter the
environment in the lungs or other parts of the body. The
human hookworm Necator however does migrate through
the lungs at the early stages of infection but here the ques-
tion remains if the dose (10 larvae) is sufficient to induce
enough of a response. Needless to say virtually all animal
studies have used significantly higher infection doses than
may be viewed as safe to ever use in humans. Finally, the
timing of infection versus the onset of seasonal allergy
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may need to be investigated as the immunomodulatory
effect of helminth infection may take longer time to
develop than what was measured in the trials to date.
In addition, the use of low dose trickle infections may
also improve immunmodulatory activity over time and
warrants further investigation.
Other uses for helminth therapy
Animal studies using the MS mouse model of experimen-
tal autoimmune encephalomyelitis (EAE) has suggested a
protective effect of helminth infections on CNS disease
progression [36,37] and a prospective study demonstrated
that 12 MS patients infected with a variety of helminth in-
fections had significantly fewer relapses and lower MRI
activity when compared to 12 non-helminth infected MS
patients over a time period of 4.5 years [38]. In a follow up
study it was further shown than when these patients
received anti-helminthic treatment their clinical presenta-
tion deteriorated and this was associated with a reduction
in IL-10 and TGF-β, and an increase in IFN-γ and IL-12
secretion from MBP peptide stimulated PBMCs [39] thus
providing further support that helminth therapy may be of
some benefit in MS patients. Subsequently, a phase 1
study for TSO treatment in 5 multiple sclerosis patients
reported fewer new lesions during and up to two months
after TSO treatment as well as increased serum levels of
IL-4 and IL-10 [40]. Several Phase 1/2 clinical trials using
TSO or hookworm in MS patients are currently registered
as recruiting or ongoing (NCT00645749, NCT01413243,
NCT01470521). In addition to MS a number of clinical
trials are currently registered for the use of TSO in
patients with psoriasis, autism and rheumatoid arthritis.
Potential for helminth products as new drugs
Helminths secrete a rich mixture of proteins, carbohy-
drates and lipids, collectively named excretory-secretory
(ES) products, into their surrounding environment and
many of these ES products have been found to exhibit a
variety of immunomodulatory activities. The best char-
acterized product to date is the ES-62 molecule from the
filarial nematode Acanthocheilonema vitae (reviewed in
[41]), a glycoprotein with potent ability to skew dendritic
cells towards promoting Th2 and inhibiting Th1 and
Th17 polarisation. In addition, ES-62 is able to inhibit
mast cell activation and induce IL-10 secretion from B
cells and macrophages. ES products from a variety of
other helminths have also been shown to drive Th2
differentiation and induce de novo differentiation of T
regulatory cells, suggesting a therapeutic potential for
inflammatory disorders. Indeed, animal studies have
demonstrated that a variety of ES products can protect
against allergen-induced airway hypersensitivity in mice,
limiting peri-bronchial inflammation by inhibiting eo-
sinophil and neutrophil infiltration of the lungs while
increasing T regulatory cell numbers and IL-10 secretion.
Moreover, animal studies have shown the potent ability of
various ES products to inhibit intestinal inflammation in
colitis models, the development of Th1-dependent type 1
autoimmune diabetes in NOD mice, reducing the devel-
opment of EAE in the mouse model of MS and blocking
the induction of collagen-induced arthritis (reviewed in
[41-43]). Taken together, all this evidence suggests an
exciting potential for new drug discoveries to be made.
However, much work remains before such products can
be taken to the clinic, as most of the ES products
remain to be characterized in detail and any problems
with potential antigenicity and/or allergenicity needs to be
resolved, such as the development of non-immunogenic
mimetics [41].
Conclusions
Without doubt there is overwhelming evidence from ani-
mal studies that helminth infections exert strong immuno-
modulatory activity and are able to inhibit, alter and modify
other ongoing immune responses. In addition, human
crossectional studies have established that many chronic
helminth infections in endemic communities are associated
with the induction of regulatory and anti-inflammatory net-
works which may act to inhibit inflammatory responses
such as autoimmune and allergic reactions. However, to
translate this into clinical helminth therapy forms have
proved less successful in the few published clinical trials
conducted so far. It may be that for worms to be successful
in controlling inflammation we need to be exposed to them
before the onset of the inflammatory condition or even that
we need to be exposed to them at a young age to allow our
immune system to co-develop together with them. In
recent years substantial interest has been generated in the
field of inflammation and autoimmunity regarding the
impact of the composition of the intestinal microbiota and
its role in shaping our immune responses both in early life
and later [44], including the importance of diet in maintain-
ing a healthy gut community [45] but it remains to be
established whether worms form a vital part of this “healthy
intestinal community”. Regardless, some promising data
has been achieved using human helminth therapy but
many questions remains to be investigated, such as the
appropriateness of the species of helminths used, whether
infections should be systemic or localized, whether the
dose should be light or heavy, of acute or chronic dur-
ation, and the role of host genetics. In addition, the use of
helminth-derived anti-inflammatory molecules is yet to be
tested on a clinical scale but may be offering a less contro-
versial, and perhaps more palatable, promising new avenue
of anti-inflammatory drug development.
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